Herceptin mod tidlige stadier af brystkræft er blevet undersøgt i ét til to år i en hovedundersøgelse med deltagelse af over 3 000 patienter, som forinden var blevet behandlet med kirurgi, kemoterapi eller strålebehandling.
In early breast cancer, Herceptin has been studied over one to two years in one main study that involved over 3,000 patients who had been first treated with surgery, chemotherapy or radiotherapy.